clevidipine has been researched along with omega-n-methylarginine in 1 studies
| Studies (clevidipine) | Trials (clevidipine) | Recent Studies (post-2010) (clevidipine) | Studies (omega-n-methylarginine) | Trials (omega-n-methylarginine) | Recent Studies (post-2010) (omega-n-methylarginine) |
|---|---|---|---|---|---|
| 127 | 19 | 62 | 4,411 | 344 | 336 |
| Protein | Taxonomy | clevidipine (IC50) | omega-n-methylarginine (IC50) |
|---|---|---|---|
| Neutrophil elastase | Homo sapiens (human) | 0.3 | |
| Proteinase-activated receptor 1 | Homo sapiens (human) | 0.0018 | |
| Nitric oxide synthase, endothelial | Bos taurus (cattle) | 7 | |
| Nitric oxide synthase, endothelial | Homo sapiens (human) | 2.9489 | |
| Nitric oxide synthase, brain | Homo sapiens (human) | 3.3983 | |
| Nitric oxide synthase, brain | Rattus norvegicus (Norway rat) | 7.5 | |
| Nitric oxide synthase, inducible | Mus musculus (house mouse) | 2.3 | |
| Nitric oxide synthase, inducible | Homo sapiens (human) | 2.9252 | |
| Collagenase 3 | Homo sapiens (human) | 0.3 | |
| Nitric oxide synthase, brain | Mus musculus (house mouse) | 4.3 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gonon, A; Gourine, A; Pernow, J; Sjöquist, PO | 1 |
1 other study(ies) available for clevidipine and omega-n-methylarginine
| Article | Year |
|---|---|
Short-acting calcium antagonist clevidipine protects against reperfusion injury via local nitric oxide-related mechanisms in the jeopardised myocardium.
Topics: Analysis of Variance; Animals; Arginine; Calcium Channel Blockers; Endothelium, Vascular; Enzyme Inhibitors; Female; Male; Myocardial Reperfusion Injury; Myocardium; Nitric Oxide; Nitric Oxide Synthase; omega-N-Methylarginine; Pyridines; Random Allocation; Substance P; Swine; Vascular Resistance | 2001 |